Lenacapavir Sodium Oral tablet ---Each film-coated tablet contains 300 mg of lenacapavir (present as 306.8 mg lenacapavir sodium)

ALI-LENA is registered in Lao PDR for use (Registration Number:  06-LM-10041-26), in combination with other antiretroviral agents, in heavily treatment-experienced adults with multidrug-resistant HIV-1 whose current antiretroviral regimen is failing because of resistance, intolerance, or safety considerations

Designed for International Registration and Supply
Aktin is working with Laos Alliance Pharmaceutical Group and on behalf of  Laos Alliance Pharmaceutical Group is seeking qualified regulatory, distribution, procurement, and commercial partners in Least Developed Countries and other underserved markets.
Our international development approach is focused on:

national product registration;
dossier and regulatory submission support;
distributor and institutional supply partnerships;
public-sector and hospital procurement;
market-specific packaging and labeling;
reliable finished-dose manufacturing and supply.

[1].Yant SR, Mulato A, Pacheco D, et al. A highly potent and long-acting HIV-1 capsid inhibitor with a novel mechanism of action. Antimicrob Agents Chemother. 2019;63(8):e00726-19. doi:10.1128/AAC.00726-19.

[2].Bester SM, Wei G, Zhao H, et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science. 2020;370(6514):360-364. doi:10.1126/science.abb4808.

[3].Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020;584(7822):614-618. doi:10.1038/s41586-020-2443-1.